Arthrosi Announces Multiple Presentations at the American College of Rheumatology (ACR) Convergence 2023
SAN DIEGO, Oct. 16, 2023 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company developing treatments to reduce uric acid levels, dissolve uric acid crystals and prevent joint damage in gout patients, today announced the acceptance of three poster presentations and one late breaking oral presentation at the American College of Rheumatology (ACR) Convergence 2023 meeting, being held in San Diego, CA on November 10-15, 2023.